A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Must have received: anti-plasma cell-directed therapy

Relapsed disease or refractory disease defined as a need for additional therapy after at least 1 line of anti-plasma cell-directed therapy.

Cannot have received: CAR-T cell therapy

Prior CAR T cell therapy directed at any target

Cannot have received: BCMA-targeting therapy

Prior BCMA-targeting therapy

Cannot have received: T cell engaging therapy

Prior treatment with any FDA approved or investigational T cell engaging therapies (including T cell-directed bispecific or trispecific therapies) at any target within the last 6 months.